NCT02180438View on ClinicalTrials.gov

An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
HIV-2 Infection
Interventions
DRUG

Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks

Trial Locations (1)

Unknown

Clinique des Maladies Infectieuses Ibrahima DIOP Mar/CRCF, Centre Hospitalier Universitaire de Fann, Dakar

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Clinique des Maladies Infectieuses Ibrahima DIOP Mar/CRCF, Centre Hospitalier Universitaire de Fann

UNKNOWN

collaborator

Gilead Sciences

INDUSTRY

lead

University of Washington

OTHER

NCT02180438 - An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal | Biotech Hunter | Biotech Hunter